Market Cap | 582.48K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -52.26M | Forward P/E | -0.01 | EPS next Y | - | 50D Avg Chg | -92.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
Dividend | N/A | Price/Book | 0.02 | EPS next 5Y | 20.40% | 52W High Chg | -100.00% |
Recommedations | 2.00 | Quick Ratio | 1.59 | Shares Outstanding | 68.53M | 52W Low Chg | 13.00% |
Insider Own | 7.67% | ROA | -38.12% | Shares Float | 52.75M | Beta | 1.57 |
Inst Own | 1.43% | ROE | -118.86% | Shares Shorted/Prior | 1.42M/256.67K | Price | 0.00850 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 889,084 | Target Price | 9.00 |
Oper. Margin | - | Earnings Date | Jul 24 | Volume | 1,943,400 | Change | -92.64% |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Piper Sandler | Neutral | Oct 13, 22 |
HC Wainwright & Co. | Neutral | Aug 2, 22 |
Oppenheimer | Outperform | Apr 21, 22 |
HC Wainwright & Co. | Buy | Feb 23, 21 |
HC Wainwright & Co. | Buy | Jul 7, 20 |
Cantor Fitzgerald | Overweight | Jun 16, 20 |
Oppenheimer | Outperform | Dec 24, 19 |
H.C. Wainwright | Buy | Aug 29, 19 |
Cantor Fitzgerald | Overweight | Nov 15, 18 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Weber David Allen | President & CEO President & CEO | Mar 25 | Sell | 2.4 | 19,269 | 46,246 | 377,499 | 03/29/22 |
Savel Robert Michael II | Chief Technical Offi.. Chief Technical Officer | Mar 25 | Sell | 2.4 | 5,699 | 13,678 | 145,735 | 03/29/22 |
Foster Alan Charles | Chief Scientific Off.. Chief Scientific Officer | Mar 25 | Sell | 2.4 | 4,386 | 10,526 | 177,017 | 03/29/22 |
Cayer Paul E | Ch. Financial & Busi.. Ch. Financial & Business Offcr | Mar 25 | Sell | 2.4 | 9,639 | 23,134 | 223,787 | 03/29/22 |
Lichter Jay | Director Director | Mar 02 | Sell | 2.86 | 893,828 | 2,556,348 | 113,935 | 03/02/21 |
Lichter Jay | Director Director | Feb 25 | Sell | 2.94 | 1,082,353 | 3,182,118 | 431,015 | 02/25/21 |